ArticleFrontiers in oncology2025
Risk modeling for esophageal cancer based on adaptive Lasso and Cox regression.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Esophageal cancer (EC) is one of the most aggressive tumor types worldwide, and malnutrition is extremely common among EC patients. By identifying EC biomarkers and conducting risk assessments on patients, more accurate diagnosis and treatment plans can be developed to prolong patients' survival. Methods: This study developed a risk assessment model for post-surgical EC patients using clinical data from patients who underwent esophagectomy. Prognostic factors influencing survival were evaluated using Adaptive Lasso for variable selection, followed by Cox proportional hazards regression and Receiver Operating Characteristic (ROC) curve. Among multiple clinical variables, the International Normalized Ratio (INR) emerged as the most significant predictor of survival. Results: Elevated INR levels were significantly associated with improved 3-year and 5-year survival outcomes compared to the Prognostic Nutritional Index (PNI). Patients with higher INR exhibited notably better postoperative survival rates. Further analysis demonstrated that INR was significantly correlated with the final differentiation degree, final infiltration degree, and final positive/negative status of EC. Discussion: INR serves as a valuable and independent prognostic biomarker for postoperative survival assessment in EC patients. Incorporating INR into clinical risk models can enhance the accuracy of prognosis and assist clinicians in optimizing individualized therapeutic strategies for surgical EC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.